BioSpace News Archive

The Janssen Pharmaceutical Companies of Johnson & Johnson announced new results from a cohort of the Phase 1b MajesTEC-2 study of TECVAYLI™, a first-in-class, BCMAxCD3 bispecific T-cell engager antibody, in combination with DARZALEX FASPRO® and lenalidomide.

Tessa Therapeutics Ltd. announced enhanced clinical data from an ongoing Phase 1 study of TT11X, an allogeneic “off the shelf” CD30.CAR-modified Epstein-Barr virus-specific T-cell therapy being co-developed by Baylor College of Medicine and Tessa.

argenx SE announced that data from its Phase 3 ADVANCE trial will be presented during the plenary session at the 64th American Society of Hematology Annual Meeting & Exposition in New Orleans, LA.

AltruBio Inc. announced the presentation of new data from its completed Phase 1b clinical trial evaluating ALTB-168 in patients with steroid-refractory or treatment-refractory acute graft-versus-host-disease at the 64th American Society of Hematology Annual Meeting, taking place December 10-13, 2022 in New Orleans, La.

Adaptive Biotechnologies Corporation announced new data demonstrating the strengths of Adaptive’s next-generation sequencing -based clonoSEQ® Assay in measuring minimal residual disease in blood cancer patients.

Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, announced positive safety and efficacy data from the Company’s ongoing Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell NHL.

Syros Pharmaceuticals announced data from the safety lead-in portion of its ongoing SELECT-AML-1 Phase 2 trial evaluating tamibarotene, an oral, selective retinoic acid receptor alpha agonist, in combination with venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia and RARA gene overexpression.

Innate Pharma SA presented data from a preliminary analysis of the TELLOMAK Phase 2 trial demonstrating clinical activity and a favorable safety profile for lacutamab, a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, in patients with advanced Sézary syndrome, a form of T cell lymphoma.

Kura Oncology, Inc. announced updated clinical data from KOMET-001, a Phase 1/2 trial of the Company’s potent and selective menin inhibitor, ziftomenib, including an encouraging safety and tolerability profile and clinical activity in patients with relapsed/refractory acute myeloid leukemia.

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics announced an oral, encore presentation of clinical data from patients with sickle cell disease or transfusion-dependent beta-thalassemia treated with the investigational therapy exagamglogene autotemcel in CLIMB-111 or CLIMB-121 and followed in CLIMB-131, a long-term follow-up study.